As the year draws to a close, Wall Street is set to crown Eli Lilly (NYSE:LLY) among the best in Big Pharma, while Novo ...

Both companies are longtime leaders in the pharmaceutical industry and have been making breakthroughs and delivering ...

A specific class of anti-inflammatory drugs can help children avoid a debilitating complication of Crohn's disease, a new ...

The U.S. Food and Drug Administration (FDA) has proposed a new rule to require standardized testing of talc-containing ...

Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...

CEO's use of Eli Lilly's (LLY) weight loss drug Mounjaro over Novo Nordisk's (NVO) rival product, Ozempic. Read more here.

The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...

Shares of Eli Lilly & Co. LLY sank 0.08% to $795.67 Tuesday, on what proved to be an all-around favorable trading session for ...

The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to ...

The drugs were first approved to treat type 2 diabetes – and that's what the FDA said daily injections of liraglutide could ...

Lilly and Novo still dominate the market for weight-loss and diabetes drugs, but the race is heating up in more ways than one ...

Eli Lilly said the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, the first and ...